Axe Out NF2
What is Axe Out NF2?
A Campaign to raise $100,000 to fund one of the three research laboratories NF2 BioSolutions supports – the Brenner Lab at Massachusetts General Hospital. The specific research is the Tumor-targeting bacteria approach - Our newest approach toward fighting NF2.
At Harvard Medical School/ Mass General Hospital, Boston, NF2 BioSolutions is working with Dr. John Mekalanos’s lab and Dr Brenner’s lab. A genetically modified bacteria is introduced intratumorally to kill the NF2 tumor cells via several mechanisms including direct killing, inducing an anti-tumor immune response - immunotherapy - and inhibiting blood vessel formation. It has been shown to work in Brenner’s lab on NF2 mice. Together, Dr Brenner and Dr Mekalanos (world known bacteria researcher) will be working at optimizing the bacteria to be a more effective tumor killer machine. Bacterial cancer therapy has been proven safe and well tolerated in multiple clinical trials. For example it is the treatment of choice for treating bladder cancer in a non-invasive manner, and it has a 50% cure rate. Trials on mice have proven its efficacy. Work is in progress to genetically modify the bacteria.
This research funding will lead to the ability to submit an IND (Investigative New Drug) application with the FDA.
Watch Dr Brenner and Dr Mekalanos explaining this novel research : https://nf2biosolutions.org/events/bacteriotherapy-for-nf2-webinar-june-2020/
Our Goal is to raise $100,000 by August 2020 to accelerate the Tumor-targeting bacteria approach at the Brenner Lab and accelerate our efforts to find a cure for NF2.
Who We are?
NF2 BioSolutions – Founded in mid-2018, we are a 501c3 non-profit organization that seeks a cure for NF2 by vigorously supporting and advancing existing and next generation biomedical technologies, such as gene therapy and immunotherapy. We do this by collaborating with three world-renown labs to accelerate gene therapy research for NF2. Nonprofit Tax Id: 83-0940046